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Abstract 
Objectives: Oral submucous fibrosis (OSMF) is the most prevalent precancerous condition in India. Low levels of 
lipids serves as a marker and prognostic indicator in the early detection of oral precancerous and cancerous states. 
In spite of the high prevalence and its potential to undergo malignant transformation, this condition has not widely 
been investigated with respect to the serum lipid levels. In the present study, an attempt was made to analyze the 
complete serum lipid profile, total cholesterol (TC), triglycerides (TG), high density lipoprotein (HDL) choleste-
rol, low density lipoprotein (LDL) cholesterol and very low density lipoprotein (VLDL) cholesterol in OSMF and 
controls.
Material and Methods:  The study was conducted in 45 clinically and histopathologically diagnosed cases of OSMF 
and 45 age and sex matched controls. The complete lipid profile including TC, TG, HDL cholesterol, LDL choles-
terol and VLDL cholesterol was analyzed.
Results: The serum lipid levels were significantly lower in the patients with OSMF than in the controls. When the 
values were compared between different disease stages, the maximum reduction of lipids was evident for stage 3 
OSMF. From the present results, it is evident that the level of serum lipids decreases with progression of the disea-
se. 
Conclusions: From these findings, it appears that the decrease in the lipid levels may be considered as a useful 
marker in the early diagnosis of oral premalignant condition like OSMF.
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Introduction
Oral submucous fibrosis [OSMF] is a chronic debili-
tating disease and a premalignant condition of the oral 
cavity (1). Oral cancer is the leading cause of morbidity 
and mortality in India and is most commonly preceded 
by clinically definable premalignant lesions and condi-
tions (2).  OSMF is regarded as a precancerous condition 
and shows a significant tendency to develop cancer (3).  
Over the years, the incidence of OSMF has increased 
in various parts of the Indian subcontinent (4). Murti et 
al. (5) demonstrated a malignant transformation rate of 
7.6% over a 17-year observation period. Therefore, it 
is also equally important to detect and control the pre-
malignant lesions and conditions (3). Early detection of 
these conditions can dramatically improve the treatment 
outcome and prognosis in such patients (2).
In recent years, emphasis has been placed on detecting 
molecular markers from body fluid, such as saliva, urine 
and others, for detecting cancer, predicting prognosis, 
and monitoring disease progression. The idea of scree-
ning and following patients with malignancy by blood-
based tests is appealing from several points of view in-
cluding its ease, economic advantage, non-invasiveness, 
and possibility of repeated sampling (6).
Usefulness of variations in tissue ⁄ blood cholesterol le-
vels in diagnosis and treatment of various diseases has 
been studied by several workers. Although, its prime 
role in pathogenesis of coronary heart diseases has been 
consistently found, researchers have reported an asso-
ciation of plasma ⁄ serum lipids and lipoproteins with 
different cancers (7-10). An alteration in the circulatory 
cholesterol levels has been found to be associated in the 
etiology of breast cancer and colorectal cancer (11-13). 
Lipids may not play a role in carcinogenesis but a lower 
level of lipids may indicate rapidly dividing cells in ma-
lignancy. This can serve as a marker in early neoplastic 
changes, in follow up cases and as a prognostic indi-
cator of disease. The mechanism for the association of 
cancer with cholesterol remains controversial. The exact 
mechanism of its role in carcinogenesis is not clearly 
defined. Cell membrane is essential for cell survival as 
well as biological functions (14). It is believed that to-
bacco carcinogens induce generation of free radicals and 
reactive oxygen species, which are responsible for high 
rate of oxidation ⁄ peroxidation of polyunsaturated fatty 
acids. This peroxidation further releases peroxide radi-
cals. This affects essential constituents of cell membrane 
and might be involved in carcinogenesis ⁄ tumorigenesis 
(15). Lipids play a key role in maintenance of cell in-
tegrity. Because of lipid peroxidation, there is a grea-
ter utilization of lipids including TC, lipoproteins, and 
triglycerides for new membrane biogenesis. Cells fulfill 
these requirements from circulation either by synthesis 
through the metabolism or from degradation of major 
lipoprotein fraction such as VLDL, LDL, or HDL (16).
Rose et al. (17) reported an inverse association between 
blood cholesterol level and the risk of cancer and provi-
ded a base for further epidemiological research. Since 
then, conflicting hypotheses have been put forward by 
many workers. Several authors propose that hypocho-
lesterolemia is a predisposing factor for cancer develo-
pment (18). Only a few reports are available on plasma/
serum lipid profile in head and neck lesions (16). Howe-
ver, these previous studies were limited by the fact that 
they evaluated lipid profile only in cancer patients, whe-
reas the present study evaluated lipid profile in the oral 
premalignant condition like OSMF. 
In spite of the high prevalence and its potential to un-
dergo malignant transformation, OSMF has not widely 
been investigated with respect to the serum lipid levels. 
Moreover, to our knowledge, literature pertaining to 
serum lipid levels in relation to OSMF and its clinical 
grading is rare. In the present study, an attempt was made 
to analyze the complete serum lipid profile in OSMF pa-
tients. Further, in this study the comparison in the serum 
lipid profile with grading in OSMF was done.
Material and Methods 
The study was conducted in 45 clinically and histopa-
thologically diagnosed cases of OSMF who attended the 
Department Of Oral Medicine and Radiology, Institute 
Of Dental Sciences, Bareilly, Uttar Pradesh-India. All the 
patients underwent recording of detailed history, and cli-
nical diagnosis was made on the presence of characteris-
tic features like vesicles, ulceration, mucosal blanching, 
burning, stiffness of oral mucosa, presence of characte-
ristic fibrous bands and progressive inability to open the 
mouth. Also, histopathological examination was carried 
out in all the cases following incisional biopsy from the 
most affected area of the buccal mucosa. OSMF was di-
vided clinically and functionally into three stages accor-
ding to the criteria reported by Haider et al. (19), based 
on the presence of fibrous bands at various anatomical 
sites, and functional staging was based on the degree of 
mouth opening.  
Clinical Staging:
• Stage 1: Faucial bands only
• Stage 2: Faucial and buccal bands
• Stage 3: Faucial, buccal and labial bands
Functional Staging:
• Stage 1: Mouth opening >20 mm
• Stage 2: Mouth opening 11-19 mm
• Stage 3: Mouth opening <10 mm
45 healthy individuals, matched for age and sex, who 
consecutively presented at the same department for va-
rious other complaints, and had no adverse habits or oral 
lesions, or any other major illness in recent past, were in-
cluded as controls. Informed consent was obtained from 
patients in both the case and control groups. The study 
was approved by the institutional ethical committee. 
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Exclusion criteria were patients with systemic diseases/
conditions that may be associated with alterations in the 
serum level of lipid profile like obese subjects weighing 
more than 20% above their ideal weight, known cases of 
uncontrolled diabetes mellitus, thyroid disorder, cardiac 
patients, liver dysfunction, malabsorption syndrome or 
those refusing for biopsy procedure and patients who 
had undergone or was on treatment for OSMF.  
The subjects of the study were as follows:
• Group I [Clinical and functional stage 1 OSMF]: 15 
patients
• Group II [Clinical and functional stage 2 OSMF]: 15 
patients 
• Group III  [Clinical and functional stage 3 OSMF]: 15 
patients
• Group IV [Controls]: 45 patients
All those patients who fulfill the above mentioned crite-
ria were included in the study. 
- Estimation of lipid profile
First, the details of each patient, including medical his-
tory, were taken. After a clinical diagnosis of OSMF had 
been made, the purpose and procedure was explained 
to each patient, who then provided informed consent to 
participate. The patient was then asked to attend the next 
morning with a minimum of 12 hour of fasting for blood 
examination for complete lipid profile.  Upon retur-
ning, the patient was asked to sit comfortably in a den-
tal chair in a reclining position. A tourniquet was then 
applied above the right cubital fossa, and 3 ml of fasting 
blood was collected from the most prominent vein under 
aseptic conditions and was stored in test tubes.  After 
the blood had coagulated, the test tube containing the 
blood was subjected to centrifugation for about 4-5 min 
at 2500 rpm. The test tube was then removed from the 
centrifuge, and the serum layer was pipetted into a vial, 
which was then stored in a refrigerator under protection 
from light. The serum lipid profile was analyzed using 
the kit Erba Mannheim [Transasia bio-medicals limited, 
Solan, India] as per instructions provided by the manu-
facture, using semi-auto analyser. Complete lipid profile 
was checked in each case.  TC, TG, HDL cholesterol, 
LDL cholesterol and VLDL cholesterol were monitored 
using Modified Roeschlau’s method for cholesterol, me-
thod of Wako and the modifications by McGowan et al 
and Fossati et al for triglycerides and  Phosphotungstic 
Acid method for HDL.
VLDL and LDL levels were calculated using Friedwald’s 
formula:
• VLDL= Triglycerides/5
• LDL= Total Cholesterol – [VLDL+HDL]
- Statistical analysis
All the variables from the study were statistically analy-
zed using the Statistical Package for the Social Scien-
ces program [SPSS version 13.0]. Analysis of variance 
[ANOVA] was used to assess the statistical significance 
of differences between the stages of OSMF and the con-
trol group. Student’s t-test was used to compare serum 
lipid profile in all the three case groups with those in the 
control group.
Results
The present study comprises of 90 subjects, of whom 64 
were males and 26 were females. Group IV comprised of 
45 age and sex matched healthy individuals without any 
contributory habits or premalignant lesions/conditions. 
Group I, II, III comprised of 11, 10, 12 males and 4, 
5, 3 females, respectively. The mean age of the patients 
in group I, II, III and IV was 25.13 years, 27.60 years, 
34.53 years and 29.09 years respectively with most of 
the patients in the second and third decades of life. All 
of the patients had been taking areca nut in one form or 
another. The mean serum TC, serum HDL cholesterol, 
serum LDL, serum VLDL and serum TG levels in oral 
submucous fibrosis group were 151.07 mg/dL, 37.80 mg/
dL, 95.15 mg/dL, 18.11 mg/dL and 94.18 mg/dL respec-
tively. However, in the control group the corresponding 
values were 191.42 mg/dL, 51.36 mg/dL, 113.64 mg/dL, 
26.43 mg/dL and 132.16 mg/dL respectively. (Table 1) 
A statistically significant reduction [P<0.001] was noted 
between the control group and OSMF cases.
CONTROL
(n = 45)
CASES
(n = 45)
‘t’ 
value
P value
TC 191.42 ± 15.66 151.07 ± 20.98 10.340 <0.001**
HDL 51.36 ± 10.30 37.80 ± 5.476 7.790 <0.001**
LDL 113.64 ± 14.88 95.15 ± 12.733 6.330 <0.001**
VLDL 26.43 ± 7.945 18.11 ± 8.05 4.932 <0.001**
TG 132.16 ± 39.72 94.18 ± 39.23 4.563 <0.001**
** p < 0.001; Highly significant
Table 1. Comparison of mean serum lipid profile among control group 
and OSMF cases.
Similarly, in different stages of OSMF i.e stage 1, stage 
2 and stage 3, these values were 174.20 mg/dL, 152.27 
mg/dL and 126.73 mg/dL for TC; 42.47 mg/dL, 38.20 
mg/dL and 32.73 mg/dL for HDL; 106.04 mg/dL, 97.27 
mg/dL and 82.15 mg/dL for LDL; 25.69 mg/dL, 16.80 
mg/dL and 11.85 mg/dL for VLDL; and 128.47 mg/
dL, 92.80 mg/dL and 61.27 mg/dL for TC, respectively. 
These values were found to decrease progressively as 
one moved from control group to that of OSMF cases. It 
also shows that as the disease progresses i.e from OSMF 
stage 1 to stage 3, there is a gradual fall in lipid profile 
levels (Table 2).
In inter-group and intra-group comparisons of serum li-
pid, for all variables p-value using ANOVA showed that 
four groups differ significantly that is non-homogeneity 
for the means of four groups (Table 3).
For pair-wise comparison a Post-hoc Tukey test was 
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conducted. It showed that for TC all pairwise differences 
were statistically significant. For HDL all pairwise diffe-
rence was statistically significant except for Group I & 
II and Group II & III. For LDL all pairwise differences 
were statistically significant except for Group I & IV and 
Group I & II.  For both VLDL and TG all pairwise diffe-
rences were statistically significant except for Group I & 
IV and Group II & III (Table 4).
Discussion
Oral submucous fibrosis is a chronic, insidious, disa-
bling precancerous condition of the oral cavity (20). It 
has always been a challenging disease with high preva-
lence in India (21).  In spite of the high prevalence of 
premalignant condition like OSMF in India and their 
potential to undergo malignant transformation, this con-
dition has not widely been investigated with respect to 
the serum lipid levels. Early detection is also called as 
Group I (stage 1)
(n=15)
Group II (stage 2)
(n=15)
Group III (stage 3)
(n=15)
Group IV (control)
(n = 45)
TC 174.20 ± 4.34 152.27 ± 9.96 126.73 ± 7.45 191.42 ± 15.66
HDL 42.47 ± 3.25 38.20 ± 3.12 32.73 ±  4.78 51.36±10.30
LDL 106.04 ± 8.55 97.27 ± 9.47 82.15 ± 5.79 113.64±14.88
VLDL 25.69 ± 5.56 16.80 ± 7.59 11.85 ± 3.10 26.43±7.945
TG 128.47± 27.82 92.80± 37.33 61.27 ± 15.76 132.16±39.72
Table 2. Mean serum lipid profile among control group and different stages of OSMF.
Sum of Squares Df Mean Square F value P value
TC Between Groups 53573.378 3 17857.793 116.089 <0.00001
Within Groups 13229.244 86 153.828
Total 66802.622 89
HDL Between Groups 4848.578 3 1616.193 26.316 <0.0001
Within Groups 5281.618 86 61.414
Total 10130.196 89
LDL Between Groups 12069.496 3 4023.165 27.675 <0.0001
Within Groups 12501.854 86 145.370
Total 24571.350 89
VLDL Between Groups 3031.811 3 1010.604 20.922 <0.0001
Within Groups 4154.073 86 48.303
Total 7185.883 89
TG Between Groups 66363.522 3 22121.174 18.421 <0.0001
Within Groups 103272.978 86 1200.849
Total 169636.500 89
Table 3. ANOVA test for serum lipid profile among various groups.
Groups TC HDL LDL VLDL TG
I-IV Mean difference
P value
17.22
<0.001**
8.889
0.001*
7.59
0.157NS
0.73
0.984NS
3.68
0.984NS
II-IV Mean difference
P value
39.15
<0.001**
13.15
<0.001**
16.36
<0.001**
9.63
<0.001**
39.35
0.001*
III-IV Mean difference
P value
64.68
<0.001**
18.62
<0.001**
31.48
<0.001**
14.57
<0.001**
70.88
<0.001**
I-II Mean difference
P value
21.93
<0.001**
4.26
0.447NS
8.77
0.199NS
8.89
0.004*
35.66
0.030*
I-III Mean difference
P value
47.46
<0.001**
9.73
0.006*
23.89
<0.001**
13.84
<0.001**
67.20
<0.001**
II-III Mean difference
P value
25.53
<0.001**
5.46
0.231NS
15.12
0.005*
4.94
0.216NS
31.53
0.068NS
NS: p > 0.05; Not Significant; * p < 0.05; Significant; ** p < 0.001; Highly significant
Table 4. Multiple comparison of serum lipid profile among various groups using Post-Hoc Tukey test.
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secondary prevention. It is therefore important to identi-
fy new diagnostics and predictive approaches.
In this study, an attempt was made to analyze serum li-
pid levels in patients with OSMF in comparison with 
normal healthy individuals, thereby providing a marker 
and prognostic indicator in the early detection of oral 
cancer. An attempt was also made to compare these le-
vels among different stages of the disease.
The mean age of our study patients was 29.09 years. Most 
of our patients were in the second and third decades of 
life. Among our 45 OSMF patients, 32 were males and 
13 were females. All the patients in our study had been 
chewing areca nut in some form. Areca nut chewing has 
been identified as the most important etiological factor 
of OSMF. A statistically significant reduction [P<0.001] 
was noted in serum TC, serum TG, serum HDL, serum 
LDL and serum VLDL between the control group and 
OSMF cases. Similarly, in different stages of OSMF i.e 
stage 1, stage 2 and stage 3, these values were found to 
decrease progressively as one moved from control group 
to that of OSMF cases. It also shows that as the disease 
progresses i.e from OSMF stage 1 to stage 3, there is 
a gradual fall in lipid profile levels. The reduced levels 
of serum lipid profile in OSMF patients may be a con-
sequence of disease, probably mediated by the greater 
utilization of lipids for new membrane biogenesis.
Tilakaratne et al. (22) reported that areca nut is the main 
etiological factor for OSMF. Excessive use of areca nut 
may cause fibrosis due to increased synthesis of collagen 
and induce the production of free radicals and reactive 
oxygen species, which are responsible for high rate of 
oxidation/peroxidation of polyunsaturated fatty acids 
which affect essential constituents of cell membrane and 
might be involved in tumorigenesis (21). Because of the 
lipid peroxidation, there is a greater utilization of lipids 
including lipoproteins, total cholesterol and triglyceri-
des for new membrane formation. Cells fulfill these re-
quirements either from circulation or from degradation 
of major lipoprotein fractions like VLDL, LDL or HDL 
(16). Lower levels of lipids thus result from increased 
utilization of lipids by the tumor cells for synthesis of 
cell membrane.
The results of the present study clearly shows that the 
serum TC, HDL, LDL, VLDL and TG were significantly 
reduced in OSMF patients group when compared with 
the control group. Patel et al. (16) showed the similar 
observations in patients with oral squamous cell carci-
noma. They found a significant decrease in plasma TC, 
HDL, VLDL and TG but LDL cholesterol levels did not 
reveal any significant difference, whereas in our study 
significant decrease in LDL levels in OSMF was seen as 
compared to controls. Similarly, Lohe et al. (3) reported 
a significant decrease in TC, and HDL in oral precance-
rous conditions, however, LDL, VLDL, and triglyceride 
did not reveal any significant difference.
Conclusions
The results of the present study show the evidence of 
an inverse relationship between serum lipid profile and 
OSMF. From these findings, it appears that the decrease 
in the lipid levels may be considered as a useful marker 
in the early diagnosis of oral premalignant condition like 
OSMF. Lipid profile can be added on to other tests as an 
additional indicator and can serve as another evaluating 
parameter to denote initial changes occurring during car-
cinogenesis. However, this will also have to be confir-
med by using a larger sample size.
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